Trial Outcomes & Findings for Opioid Analgesic Reduction Study (OARS) - Pilot (NCT NCT05283499)

NCT ID: NCT05283499

Last Updated: 2023-06-06

Results Overview

Average Pain (self reported by subject) rated on numeric rating scale (0=no pain, 10=worst pain imaginable)

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

53 participants

Primary outcome timeframe

1st day

Results posted on

2023-06-06

Participant Flow

Participant milestones

Participant milestones
Measure
Opioid
Combination analgesic of hydrocodone 5mg/acetaminophen350 mg OPIOID: Analgesic assignment
Non-Opioid
Combination analgesic of ibuprofen 400mgacademinophen 350mg NON-OPIOID: Analgesic assignment
Overall Study
STARTED
26
27
Overall Study
COMPLETED
25
25
Overall Study
NOT COMPLETED
1
2

Reasons for withdrawal

Reasons for withdrawal
Measure
Opioid
Combination analgesic of hydrocodone 5mg/acetaminophen350 mg OPIOID: Analgesic assignment
Non-Opioid
Combination analgesic of ibuprofen 400mgacademinophen 350mg NON-OPIOID: Analgesic assignment
Overall Study
Did not receive intervention
1
2

Baseline Characteristics

Opioid Analgesic Reduction Study (OARS) - Pilot

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Opioid
n=25 Participants
Combination analgesic of hydrocodone 5mg/acetaminophen350 mg OPIOID: Analgesic assignment
Non-Opioid
n=25 Participants
Combination analgesic of ibuprofen 400mgacademinophen 350mg NON-OPIOID: Analgesic assignment
Total
n=50 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
25 Participants
n=5 Participants
25 Participants
n=7 Participants
50 Participants
n=5 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Sex: Female, Male
Female
12 Participants
n=5 Participants
13 Participants
n=7 Participants
25 Participants
n=5 Participants
Sex: Female, Male
Male
13 Participants
n=5 Participants
12 Participants
n=7 Participants
25 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
6 Participants
n=5 Participants
7 Participants
n=7 Participants
13 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
19 Participants
n=5 Participants
18 Participants
n=7 Participants
37 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
4 Participants
n=5 Participants
3 Participants
n=7 Participants
7 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
1 Participants
n=7 Participants
1 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
10 Participants
n=5 Participants
7 Participants
n=7 Participants
17 Participants
n=5 Participants
Race (NIH/OMB)
White
3 Participants
n=5 Participants
11 Participants
n=7 Participants
14 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
3 Participants
n=5 Participants
1 Participants
n=7 Participants
4 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
5 Participants
n=5 Participants
2 Participants
n=7 Participants
7 Participants
n=5 Participants
Region of Enrollment
United States
25 participants
n=5 Participants
25 participants
n=7 Participants
50 participants
n=5 Participants

PRIMARY outcome

Timeframe: 1st day

Average Pain (self reported by subject) rated on numeric rating scale (0=no pain, 10=worst pain imaginable)

Outcome measures

Outcome measures
Measure
Opioid
n=25 Participants
Combination analgesic of hydrocodone 5mg/acetaminophen350 mg OPIOID: Analgesic assignment
Non-Opioid
n=25 Participants
Combination analgesic of ibuprofen 400mgacademinophen 350mg NON-OPIOID: Analgesic assignment
Pain Level
5.67 score on a scale
Standard Error 0.59
4.09 score on a scale
Standard Error 0.59

PRIMARY outcome

Timeframe: Average for the 1st and 2nd day

Average Pain (self reported by subject) rated on numeric rating scale (0=no pain, 10=worst pain

Outcome measures

Outcome measures
Measure
Opioid
n=25 Participants
Combination analgesic of hydrocodone 5mg/acetaminophen350 mg OPIOID: Analgesic assignment
Non-Opioid
n=25 Participants
Combination analgesic of ibuprofen 400mgacademinophen 350mg NON-OPIOID: Analgesic assignment
Pain Level
5.10 score on a scale
Standard Error 0.58
3.57 score on a scale
Standard Error 0.58

PRIMARY outcome

Timeframe: Average for the first seven days post surgery

Pain (self reported by subject) rated on numeric rating scale (0=no pain, 10=worst pain

Outcome measures

Outcome measures
Measure
Opioid
n=25 Participants
Combination analgesic of hydrocodone 5mg/acetaminophen350 mg OPIOID: Analgesic assignment
Non-Opioid
n=25 Participants
Combination analgesic of ibuprofen 400mgacademinophen 350mg NON-OPIOID: Analgesic assignment
Pain Level
4.00 score on a scale
Standard Error 0.54
2.74 score on a scale
Standard Error 0.54

SECONDARY outcome

Timeframe: 1st night

Quality of overall sleep (self reported by subject) rated on numeric rating scale (0=best possible sleep possible, 10=worst possible sleep possible)

Outcome measures

Outcome measures
Measure
Opioid
n=25 Participants
Combination analgesic of hydrocodone 5mg/acetaminophen350 mg OPIOID: Analgesic assignment
Non-Opioid
n=25 Participants
Combination analgesic of ibuprofen 400mgacademinophen 350mg NON-OPIOID: Analgesic assignment
Sleep Quality
5.45 score on a scale
Standard Error 0.69
3.76 score on a scale
Standard Error 0.70

SECONDARY outcome

Timeframe: Average for the 1st and 2nd night

Quality of overall sleep (self reported by subject) rated on numeric rating scale (0=best possible sleep possible, 10=worst possible sleep possible)

Outcome measures

Outcome measures
Measure
Opioid
n=25 Participants
Combination analgesic of hydrocodone 5mg/acetaminophen350 mg OPIOID: Analgesic assignment
Non-Opioid
n=25 Participants
Combination analgesic of ibuprofen 400mgacademinophen 350mg NON-OPIOID: Analgesic assignment
Sleep Quality
5.25 score on a scale
Standard Error 0.64
3.44 score on a scale
Standard Error 0.65

SECONDARY outcome

Timeframe: Average for the 1st, 2nd and 3rd night

Quality of overall sleep (self reported by subject) rated on numeric rating scale (0=best possible sleep possible, 10=worst possible sleep possible)

Outcome measures

Outcome measures
Measure
Opioid
n=25 Participants
Combination analgesic of hydrocodone 5mg/acetaminophen350 mg OPIOID: Analgesic assignment
Non-Opioid
n=25 Participants
Combination analgesic of ibuprofen 400mgacademinophen 350mg NON-OPIOID: Analgesic assignment
Sleep Quality
4.91 score on a scale
Standard Error 0.63
3.36 score on a scale
Standard Error 0.63

SECONDARY outcome

Timeframe: Average for the first seven nights post surgery

Quality of overall sleep (self reported by subject) rated on numeric rating scale (0=best possible sleep possible, 10=worst possible sleep possible)

Outcome measures

Outcome measures
Measure
Opioid
n=25 Participants
Combination analgesic of hydrocodone 5mg/acetaminophen350 mg OPIOID: Analgesic assignment
Non-Opioid
n=25 Participants
Combination analgesic of ibuprofen 400mgacademinophen 350mg NON-OPIOID: Analgesic assignment
Sleep Quality
4.38 score on a scale
Standard Error 0.60
2.89 score on a scale
Standard Error 0.60

SECONDARY outcome

Timeframe: 1st day

Impact of pain on subject's ability to perform normal daily functions. The sum of six questions rated on a 5 point Likert Scale (1=not at all or never, 2=a little bit or rarely, 3=somewhat or sometimes, 4=quite a bit or often and 5=very much or always) The six questions are: 1) how much did pain interfere with your enjoyment of life, 2) how much did pain interfere with your ability to concentrate, 3) how much did pain interfere with your day to day activities, 4) how much did pain interfere with your enjoyment of recreational activities 5) how much did pain interfere with your tasks away form and home and 6) how often did pain keep you from socializing with others? Minimum = 6, Maximum = 30; lower is better and higher is worse outcome

Outcome measures

Outcome measures
Measure
Opioid
n=25 Participants
Combination analgesic of hydrocodone 5mg/acetaminophen350 mg OPIOID: Analgesic assignment
Non-Opioid
n=25 Participants
Combination analgesic of ibuprofen 400mgacademinophen 350mg NON-OPIOID: Analgesic assignment
Pain Interference Scale (Patient Report Outcomes Measurement Information System - PROMIS 6b )
17.62 score on a scale
Standard Error 1.27
14.34 score on a scale
Standard Error 1.26

SECONDARY outcome

Timeframe: Average for the 1st and 2nd day

Impact of pain on subject's ability to perform normal daily functions. The sum of six questions rated on a 5 point Likert Scale (1=not at all or never, 2=a little bit or rarely, 3=somewhat or sometimes, 4=quite a bit or often and 5=very much or always) The six questions are: 1) how much did pain interfere with your enjoyment of life, 2) how much did pain interfere with your ability to concentrate, 3) how much did pain interfere with your day to day activities, 4) how much did pain interfere with your enjoyment of recreational activities 5) how much did pain interfere with your tasks away form and home and 6) how often did pain keep you from socializing with others? Minimum = 6, Maximum = 30; lower is better and higher is worse outcome

Outcome measures

Outcome measures
Measure
Opioid
n=25 Participants
Combination analgesic of hydrocodone 5mg/acetaminophen350 mg OPIOID: Analgesic assignment
Non-Opioid
n=25 Participants
Combination analgesic of ibuprofen 400mgacademinophen 350mg NON-OPIOID: Analgesic assignment
Pain Interference Scale (Patient Report Outcomes Measurement Information System - PROMIS 6b )
16.21 score on a scale
Standard Error 1.18
12.91 score on a scale
Standard Error 1.19

SECONDARY outcome

Timeframe: Average for the 1st, 2nd and 3rd day

Impact of pain on subject's ability to perform normal daily functions. The sum of six questions rated on a 5 point Likert Scale (1=not at all or never, 2=a little bit or rarely, 3=somewhat or sometimes, 4=quite a bit or often and 5=very much or always) The six questions are: 1) how much did pain interfere with your enjoyment of life, 2) how much did pain interfere with your ability to concentrate, 3) how much did pain interfere with your day to day activities, 4) how much did pain interfere with your enjoyment of recreational activities 5) how much did pain interfere with your tasks away form and home and 6) how often did pain keep you from socializing with others? Minimum = 6, Maximum = 30; lower is better and higher is worse outcome

Outcome measures

Outcome measures
Measure
Opioid
n=25 Participants
Combination analgesic of hydrocodone 5mg/acetaminophen350 mg OPIOID: Analgesic assignment
Non-Opioid
n=25 Participants
Combination analgesic of ibuprofen 400mgacademinophen 350mg NON-OPIOID: Analgesic assignment
Pain Interference Scale (Patient Report Outcomes Measurement Information System - PROMIS 6b )
15.50 score on a scale
Standard Error 1.15
12.19 score on a scale
Standard Error 1.16

SECONDARY outcome

Timeframe: Average for the first seven days post surgery

Impact of pain on subject's ability to perform normal daily functions. The sum of six questions rated on a 5 point Likert Scale (1=not at all or never, 2=a little bit or rarely, 3=somewhat or sometimes, 4=quite a bit or often and 5=very much or always) The six questions are: 1) how much did pain interfere with your enjoyment of life, 2) how much did pain interfere with your ability to concentrate, 3) how much did pain interfere with your day to day activities, 4) how much did pain interfere with your enjoyment of recreational activities 5) how much did pain interfere with your tasks away form and home and 6) how often did pain keep you from socializing with others? Minimum = 6, Maximum = 30; lower is better and higher is worse outcome

Outcome measures

Outcome measures
Measure
Opioid
n=25 Participants
Combination analgesic of hydrocodone 5mg/acetaminophen350 mg OPIOID: Analgesic assignment
Non-Opioid
n=25 Participants
Combination analgesic of ibuprofen 400mgacademinophen 350mg NON-OPIOID: Analgesic assignment
Pain Interference Scale (Patient Report Outcomes Measurement Information System - PROMIS 6b )
13.74 score on a scale
Standard Error 1.12
11.01 score on a scale
Standard Error 1.13

SECONDARY outcome

Timeframe: Average for the first seven days post surgery

Subject's rating of overall satisfaction with the analgesic provided after surgery on a 5 point Likert Scale (1=very satisfied, 2=satisfied, 3=neither satisfied or dissatisfied, 4=dissatisfied, 5=very dissatisfied)

Outcome measures

Outcome measures
Measure
Opioid
n=25 Participants
Combination analgesic of hydrocodone 5mg/acetaminophen350 mg OPIOID: Analgesic assignment
Non-Opioid
n=25 Participants
Combination analgesic of ibuprofen 400mgacademinophen 350mg NON-OPIOID: Analgesic assignment
Overall Satisfaction
2.1 score on a scale
Standard Deviation 1.4
1.7 score on a scale
Standard Deviation 0.89

Adverse Events

OPIOID

Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths

NON-OPIOID

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
OPIOID
n=25 participants at risk
Received hydrocodone/acetaminophen
NON-OPIOID
n=25 participants at risk
Received ibuprofen/acetaminophen
Gastrointestinal disorders
Constipation
4.0%
1/25 • Number of events 1 • Post-operative Period -- 9 Days +/- 5 days from surgery
Adverse event is defined as an event which required a unexpected office visit or visit to an emergency room and could be related to study intervention
0.00%
0/25 • Post-operative Period -- 9 Days +/- 5 days from surgery
Adverse event is defined as an event which required a unexpected office visit or visit to an emergency room and could be related to study intervention

Additional Information

Cecile A. Feldman

Rutgers University School of Dental Medicine

Phone: 973-972-4634

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place